We found that REST levels are reduced, while p-S133-CREB1 (an indicator of CREB1 activation) and NE markers are increased, when prostate cancer cells are treated with ISO or Fsk+IBMX (Fig. 4A, Supplementary Fig. S2A, B). This evidence concerns the gene REST and prostate carcinoma.